OOCENTA
DEAD

Serial Number

87335700

Owner

ALLERGAN SALES, LLC

Filing Date

Feb 14, 2017

Add to watchlist:

No watchlists yet
View on USPTO

OOCENTA Trademark

Serial Number: 87335700

OOCENTA is a trademark filed by ALLERGAN SALES, LLC on February 14, 2017. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

ALLERGAN SALES, LLC (490 trademarks)

5 GIRALDA FARMS
MADISON, NJ 07940

Entity Type: 16

Trademark Details

Filing Date

February 14, 2017

Registration Date

Not Registered

Published for Opposition

May 30, 2017

Goods & Services

Pharmaceutical preparations used in connection with anti-aging, namely, for use in the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin, and for facial aesthetic surgery, facial aesthetic reconstruction, and breast aesthetic treatment procedures; topical antibiotics, anti-inflammatory, anti-infective, anti-glaucoma agents and decongestant formulations; sterile antibiotic ointments; ocular contact lens wetting solutions, artificial tears and pharmaceutical preparations for the treatment of minor ocular inflammations and allergic conditions; dermatological formulations, namely, medicated dry skin lotions and creams, acne medications and medicated skin lightener lotions and creams; Oral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing pharmaceutical preparations; Pharmaceutical preparations and medicines for the treatment and prevention of sexual dysfunction; Pharmaceutical preparations and medicines for the treatment of sensory organ disorders; Pharmaceutical preparations and medicines for the treatment of urogenital organ disorders; Pharmaceutical preparations and medicines for the treatment of circulatory system disorders; Pharmaceutical preparations and medicines for the treatment of cardiovascular and blood pressure; Pharmaceutical preparations for the treatment and prevention of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceutical preparations and medicines for the treatment and prevention of irritable bowel syndrome; Pharmaceutical preparations that support, encourage or promote bone strength or bone health or which are used in the treatment of bone disorders or bone diseases; Antibiotics; Antifungal preparations; Antivirals and Antiprotozoals; Pharmaceutical preparations for the prevention and treatment of bacterial infections; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of hypertension; coronary vasodilating agents; Pharmaceutical preparations for the treatment of hypothyroidism; Pharmaceutical and cosmeceutical preparations for skin care, namely, medicated skin cleansers, toners, moisturizers, rejuvenators, rehydrating creams, and lotions for the face and body

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Aug 31, 2020 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Aug 31, 2020 ABN6
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jan 17, 2020 EXRA
SOU EXTENSION 5 GRANTED
Jan 16, 2020 EX5G
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Jan 16, 2020 AITU
SOU EXTENSION 5 FILED
Jan 14, 2020 EXT5
SOU TEAS EXTENSION RECEIVED
Jan 14, 2020 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jun 18, 2019 EXRA
SOU EXTENSION 4 GRANTED
Jun 14, 2019 EX4G
SOU EXTENSION 4 FILED
Jun 14, 2019 EXT4
SOU TEAS EXTENSION RECEIVED
Jun 14, 2019 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jan 12, 2019 EXRA
SOU EXTENSION 3 GRANTED
Jan 10, 2019 EX3G
SOU EXTENSION 3 FILED
Jan 10, 2019 EXT3
SOU TEAS EXTENSION RECEIVED
Jan 10, 2019 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jul 18, 2018 EXRA
SOU EXTENSION 2 GRANTED
Jul 16, 2018 EX2G
SOU EXTENSION 2 FILED
Jul 16, 2018 EXT2
SOU TEAS EXTENSION RECEIVED
Jul 16, 2018 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Dec 12, 2017 EXRA
SOU EXTENSION 1 GRANTED
Dec 8, 2017 EX1G
SOU EXTENSION 1 FILED
Dec 8, 2017 EXT1
SOU TEAS EXTENSION RECEIVED
Dec 8, 2017 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Jul 25, 2017 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
May 30, 2017 NPUB
PUBLISHED FOR OPPOSITION
May 30, 2017 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
May 10, 2017 NONP
LAW OFFICE PUBLICATION REVIEW COMPLETED
Apr 26, 2017 PREV
ASSIGNED TO LIE
Apr 24, 2017 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
Mar 22, 2017 CNSA
EXAMINER'S AMENDMENT ENTERED
Mar 22, 2017 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Mar 22, 2017 GNEN
EXAMINERS AMENDMENT E-MAILED
Mar 22, 2017 GNEA
EXAMINERS AMENDMENT -WRITTEN
Mar 22, 2017 CNEA
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Mar 20, 2017 GNS3
LETTER OF SUSPENSION E-MAILED
Mar 20, 2017 GNSL
SUSPENSION LETTER WRITTEN
Mar 20, 2017 CNSL
ASSIGNED TO EXAMINER
Mar 11, 2017 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Feb 21, 2017 NWOS
NEW APPLICATION ENTERED
Feb 17, 2017 NWAP